JINS HOLDINGS Inc.

JINS HOLDINGS Inc., through its subsidiaries, engages in the planning, manufacturing, sales, and import/export of eyewear and fashion accessories in Japan. It offers airframes; computer glasses under the JINS SCREEN name; JINS Switch, an eyewear that uses magnet to attach sunglasses to frame; children's glasses; JINS VIOLET lenses for selectively block harmful light; JINS MEME, an eyewear, which enables visualization of one's physical and mental state; and contact lenses under the JINS 1DAY name through stores under the JINS Shibuya, JINS Harajuku, and rim of jins LUMINE Shinjuku names, as well through online and other channels. The company is also involved in the operation of shared workspaces; developing and selling work environment products; provision of workspace consulting; and contracting business for agriculture work. In addition, it operates bakery cafes. The company was formerly known as JINS Inc. and changed its name to JINS HOLDINGS Inc. in July 2019. JINS HOLDINGS Inc. was incorporated in 1988 and is headquartered in Tokyo, Japan.

JINS HOLDINGS Inc. trades as JNDOF on OTC. The company is classified in Healthcare / Medical - Instruments & Supplies and reports in USD.

The current profile places the business in Medical - Instruments & Supplies. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $97.22B of revenue and $8.33B of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

JINS HOLDINGS Inc. can be compared against peers such as Allergy Therapeutics plc, Avon Technologies Plc, Beijing Tong Ren Tang Chinese Medicine Company Limited, Boiron S.A., COLTENE Holding AG, CellaVision AB (publ).

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $1.10B, beta of 0.34, and return on equity of +26.2%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

JNDOF currently shows total debt of $5.73B and beta of 0.34. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://jinsholdings.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.